Financial Instrument [Axis]
Certificate of Deposit [Member]
Corporate Debt Securities [Member]
Measurement Frequency [Axis]
Fair Value, Measurements, Recurring [Member]
Fair Value Hierarchy and NAV [Axis]
Fair Value, Inputs, Level 1 [Member]
Fair Value, Inputs, Level 2 [Member]
Fair Value, Inputs, Level 3 [Member]
Business Acquisition [Axis]
EGEN Inc [Member]
Legal Entity [Axis]
IPR&D Drug Technology Platforms [Member]
Range [Axis]
Maximum [Member]
Contingent Consideration by Type [Axis]
Glioblastoma Multiforme Brain Cancer [Member]
Type of Arrangement and Non-arrangement Transactions [Axis]
Purchase Agreement [Member]
Ovarian Cancer [Member]
Hercules Credit Agreement [Member]
Vesting [Axis]
Second Tranche [Member]
Debt Instrument [Axis]
Counterparty Name [Axis]
Hercules [Member]
Equity Components [Axis]
Warrant [Member]
Class of Warrant or Right [Axis]
Hercules Warrant [Member]
Loan Agreement [Member]
Hercules Technology Growth Capital, Inc. [Member]
Award Type [Axis]
Stock Options [Member]
Plan Name [Axis]
2007 Stock Incentive Plan [Member]
2018 Stock Incentive Plan [Member]
Minimum [Member]
Equity Stock Awards [Member]
First Tranche [Member]
Variable Rate [Axis]
Prime Rate [Member]
Restricted Stock Awards [Member]
Lease Arrangement, Type [Axis]
Lawrenceville New Jersey [Member]
Credit Facility [Axis]
Standby Letter of Credit [Member]
EGEN Asset Purchase Agreement [Member]
Huntsville Alabama [Member]
Legal Entity of Counterparty, Type [Axis]
Hisun [Member]
Underwriting Agreement [Member]
Oppenheimer & Co. Inc. [Member]
Investor Warrants [Member]
Sale of Stock [Axis]
October 2017 Underwritten Offering [Member]
July 2017 Direct Offering [Member]
Pre-Funded Series CCC Warrants [Member]
Series AAA Warrants [Member]
Series BBB Warrants [Member]
Series DDD Warrants [Member]
February 14, 2017 Public Offering [Member]
Series AA Warrant [Member]
Pre-Funded Series BB Warrant [Member]
2013 Warrants, 2014 Warrants, and June 2016 Warrants [Member]
2015 Warrants [Member]
May 2015 Common Stock Offering [Member]
ATM Agreement [Member]
June 2016 Warrants [Member]
Geographical [Axis]
New Jersey [Member]
Horizon Technology Finance Corporation [Member]
Horizon Credit Agreement [Member]
Horizon Warrants [Member]
Horizon [Member]
LIBOR plus [Member]
Document And Entity Information
Entity Registrant Name
Entity Central Index Key
Document Type
Document Period End Date
Amendment Flag
Current Fiscal Year End Date
Entity Filer Category
Entity Common Stock, Shares Outstanding
Trading Symbol
Document Fiscal Period Focus
Document Fiscal Year Focus
Statement of Financial Position [Abstract]
ASSETS
Current assets:
Cash and cash equivalents
Investment securities - available for sale, at fair value
Accrued interest receivable on investment securities
Advances, deposits and other current assets
Subtotal current assets
Property and equipment (at cost, less accumulated depreciation and amortization of $2,899,400 and $2,838,716, respectively)
Other assets:
In-process research and development
Other intangible assets, net
Goodwill
Patent licensing fees, deposits and other assets, net
Subtotal other assets
Total assets
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable - trade
Other accrued liabilities
Deferred revenue - current portion
Subtotal current liabilities
Earn-out milestone liability
Notes payable - non-current portion
Deferred revenue - non-current portion
Other liabilities - non-current portion
Total liabilities
Commitments and contingencies
Stockholders' equity:
Preferred Stock - $0.01 par value (100,000 shares authorized; no shares issued or outstanding at June 30, 2018 and December 31, 2017)
Common stock - $0.01 par value (112,500,000 shares authorized; 17,746,619 and 17,277,299 shares issued at June 30, 2018 and December 31, 2017, respectively, and 17,746,285 and 17,276,965 shares outstanding at June 30, 2018 and December 31, 2017, respectively)
Additional paid-in capital
Accumulated other comprehensive loss
Accumulated deficit
Subtotal
Treasury stock, at cost (334 shares at June 30, 2018 and December 31, 2017)
Total stockholders' equity
Total liabilities and stockholders' equity
Property and equipment, accumulated depreciation
Preferred stock, par value
Preferred stock, shares authorized
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value
Common stock, shares authorized
Common stock, shares issued
Common stock, shares outstanding
Treasury stock, shares
Income Statement [Abstract]
Licensing revenue
Operating expenses:
Research and development
General and administrative
Total operating expenses
Loss from operations
Other (expense) income:
Loss from change in valuation of earn-out milestone liability
Investment income
Interest expense
Other (expense) income
Total other (expense) income, net
Net loss
Deemed dividend related to warrant modification
Net loss attributable to common shareholders
Net loss per common share
Basic and diluted
Weighted average shares outstanding
Basic and diluted
Statement of Comprehensive Income [Abstract]
Other comprehensive (loss) gain
Changes in:
Realized (gain) loss on investment securities recognized in investment income, net
Unrealized gain on investment securities
Change in unrealized gain on available for sale securities
Net loss
Comprehensive loss
Statement of Cash Flows [Abstract]
Cash flows from operating activities:
Non-cash items included in net loss:
Depreciation and amortization
Change in fair value of earn-out milestone liability
Deferred revenue
Stock-based compensation costs
Restricted shares issued
Amortization of deferred finance charges and debt discount associated with notes payable
Change in deferred rent liability
Net changes in:
Accrued interest on investment securities
Advances, deposits and other current assets
Accounts payable and accrued liabilities
Net cash (used in) operating activities:
Cash flows from investing activities:
Purchases of investment securities
Proceeds from sale and maturity of investment securities
Refund (deposit) on corporate office lease
Purchases of property and equipment
Net cash (used in) provided by investing activities
Cash flows from financing activities:
Proceeds from sale of common stock equity, net of issuance costs
Proceeds from notes payable, net of issuance costs
Proceeds from exercise of common stock warrants
Principal payments on notes payable
Net cash provided by financing activities
Increase in cash and cash equivalents
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period
Supplemental disclosures of cash flow information:
Interest paid
Non-cash investing and financing activities:
Fair value of warrants issued in connection with the notes payable
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business Description
Basis of Presentation
Financial Condition and Business Plan
Accounting Changes and Error Corrections [Abstract]
New Accounting Pronouncements
Earnings Per Share [Abstract]
Net Loss Per Common Share
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments
Fair Value Measurements
Business Combinations [Abstract]
Acquisition of EGEN Assets
Payables and Accruals [Abstract]
Accrued Liabilities
Debt Disclosure [Abstract]
Note Payable
Equity [Abstract]
Stockholders' Equity
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation
Earn-out Milestone Liability
Earn-out Milestone Liability
Warrants
Warrants
Commitments and Contingencies Disclosure [Abstract]
Contingent Liabilities and Commitments
Technology Development And Licensing Agreements
Technology Development and Licensing Agreements
Schedule of Cost, Fair Value and Maturities of Short Term Investments
Schedule of Unrealized Losses and Fair Value of Investment Securities
Schedule of Investment Income
Schedule of Fair Value of Assets and Liabilities
Schedule of Fair Value of Assets Acquired and Liabilities Assumed
Schedule of Other Accrued Liabilities
Schedule of Future Principle Payments, Net of Unamortized Debt Discounts
Schedule of Stock Option Awards and Restricted Stock Grants
Schedule of Assumptions Used to Determine Fair Value of Options Granted
Schedule of Changes in Earn-out Milestone Liability
Schedule of Milestone Risk Adjustment Assessment
Summary of Warrant Activity
Statement [Table]
Statement [Line Items]
Cumulated net losses
Cash, investment securities and interest receivable
Aggregate offering price, additions
Net authorized amount percentage
Number of shares of common stock issuable upon exercise of warrants and equity awards
Short-term investments - Cost
Short-term investments - Fair Value
Short-term investment maturities - Within 3 months, cost
Short-term investment maturities - Between 3-12 months, cost
Total, cost
Short-term investment maturities - Within 3 months, fair value
Short-term investment maturities - Between 3-12 months, fair value
Total, fair value
Less than 12 months, unrealized gains, fair value
Less than 12 months, unrealized losses, fair value
Investment securities - available for sale, at fair value
Less than 12 months, unrealized gains
Less than 12 months, unrealized losses
Unrealized gains (losses)
Interest and dividends accrued and paid
Realized gains
Investment income
Fair Value, Assets, Level 1 to Level 2 Transfers, Amount
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Transfers into Level 3
Investment securities, available for sale
Total purchase price for the asset acquisition
Potential future earn-out payments
Payments to Acquire Businesses, Gross
Stock issued during period, shares, acquisitions
Number of common stock issued or issuable
Indefinite lived intangible assets
Asset impairment charges, total
Finite-lived intangible assets acquired
Finite-lived intangible asset, useful life
Amortization expense
Finite-lived intangible assets, net, ending balance
Finite-lived intangible assets, accumulated amortization
Goodwill, acquisition
Property and equipment, net
In-process research and development
Other Intangible assets (Covenant not to compete)
Total assets:
Accounts payable and accrued liabilities
Net assets acquired
Amounts due to contract research organizations and other contractual agreements
Accrued payroll and related benefits
Accrued professional fees
Other
Total
Line of credit facility, maximum borrowing capacity
Proceeds from lines of credit, total
Line of credit, interest rate
Precentage of outstanding principle balance, description
Class of warrant or right, number of securities called by each warrant or right
Class of warrant or right, exercise price of warrants or rights
Debt instrument, unamortized discount, total
Percentage for original debt, amount
Debt issuance costs, gross
Debt issuance costs, net, total
Interest expense, debt, total
Amortization of debt issuance costs
Repayments of lines of credit
Payments to acquire businesses, gross
Debt instrument, basis spread on variable rate
Warrant date
Original debt, amount
2019
2020
2021
2022
2023 and thereafter
Subtotal of future principle payments
Net of unamortized debt issuance costs
Total
Nonmonetary Transaction Type [Axis]
Shelf registration statement amount
Aggregate of common and preferred stock, shares authorized
Reverse stock split
Stock issued during period split stock
Stock issued during period reverse stock split
Share-based compensation arrangement by share-based payment award, options, outstanding, number, ending balance
Class of warrant or right, outstanding
Stock issued during period, shares, new issues
Common stock, par or stated value per share
Class of warrant or right, number of securities called by warrants or rights
Warrant, description
Class of warrant or right, offered price of warrants or rights
Warrants issued, expiration period
Proceeds from issuance of common stock and warrants
Share price
Proceeds from issuance of common stock, gross
Beneficial ownership percentage threshold
Proceeds from issuance of warrants
Class of warrant or right, exercised during period
Shares issued, price per share
Class of warrant or right, term
Maximum beneficial ownership of the purchaser
Proceeds from issuance of common stock
Stock issued during period, shares, exercise of warrants
Proceeds from warrant exercises
Increase (decrease) in fair value of warrants
Aggregate offering price
Class of warrant or right, exercisable period
Offering price, description
Commission on proceeds from atm shares percent
Legal fees
Aggregate offering price, remaining amount
Options expiration period
Equity awards, number of stock authorized
Percentage of fair market value of shares
Percentage of outstanding stock determining factor for incentive stock price
Number of shares reserved for future issuance
Number of equity awards granted
Number of equity awards available for future issuance
Compensation cost
Unrecognized compensation cost related to non-vested stock based compensation
Stock based compensation cost expected to be recognized, weighted average period
Weighted average grant date fair value of stock option awards granted
Equity awards, outstanding, beginning balance
Equity awards granted
Vested and issued
Equity awards forfeited, cancelled or expired
Equity awards, outstanding, ending balance
Aggregate intrinsic value of outstanding awards, ending balance
Equity awards exercisable, ending balance
Aggregate intrinsic value of awards exercisable, ending balance
Weighted average exercise price, equity awards, outstanding, beginning balance
Weighted average exercise price, equity awards granted
Weighted average exercise price, vested and issued
Weighted average exercise price, equity awards forfeited, cancelled or expired
Weighted average exercise price, equity awards, outstanding, ending balance
Weighted average exercise price, equity awards exercisable, ending balance
Non-vested restricted stock outstanding, equity awards, outstanding, beginning balance
Non-vested restricted stock outstanding, equity awards granted
Non-vested restricted stock outstanding, vested and issued
Non-vested restricted stock outstanding, equity awards forfeited, cancelled or expired
Non-vested restricted stock outstanding, equity awards, outstanding, ending balance
Non-vested restricted stock outstanding, aggregate intrinsic value of outstanding awards, ending balance
Weighted average grant date fair value, equity awards, outstanding, beginning balance
Weighted average grant date fair value, equity awards granted
Weighted average grant date fair value, vested and issued
Weighted average grant date fair value, equity awards forfeited, cancelled or expired
Weighted average grant date fair value, equity awards, outstanding, ending balance
Weighted average contractual terms of equity awards (in years), equity awards, outstanding, ending balance
Weighted average contractual terms of equity awards (in years), equity awards exercisable, ending balance
Risk-free interest rate
Expected volatility
Expected life (in years)
Expected forfeiture rate
Expected dividend yield
Future earn-out payments
Fair value of Acquisition consideration
Risk adjusted assessment of each milestone
Estimated Time to Achieve the Milestone
Gain (Loss) from Change in Fair Value of Earn out Milestone Liability
Earn-out Milestone Liability - Schedule Of Changes In Earn-out Milestone Liability
Earn-out liabilities, beginning balance
Non-cash charge from the adjustment for the change in fair value included in net loss
Earn-out liabilities, ending balance
Risk-adjustment Assessment of each Milestone
Discount Rate
Estimated Time to Achieve (in years)
Warrants - Summary Of Warrant Activity
Number of warrants issued warrants outstanding at December 31, 2017
Number of warrants issued during the six months ended June 30, 2018
Number of Warrants Issued Warrants outstanding at June 30, 2018
Number of warrants issued aggregate intrinsic value of outstanding warrants at June 30, 2018
Number of warrants issued weighted average remaining contractual terms at June 30, 2018 (in years)
Weighted average exercise price warrants outstanding at December 31, 2017
Weighted Average Exercise Price Warrants issued during the six months ended June 30, 2018
Weighted Average Exercise Price Warrants outstanding at June 30, 2018
Area of premises
Lease term
The number of months in which free rent is provided
Payment for rent
Irrevocable and unconditional standby letter of credit
Contractual obligation reduction nineteen months from initial term
Contractual obligation remaining
Operating leases, monthly rent payment in first year
Operating leases, monthly rent payment in final year
Operating leases, monthly rent payment
Non-refundable research and development fee
Deferred revenue
Deferred revenue amortization period
Represents the additional aggregate offering price for shares of common stock that the Company may offer and sell through a sales agent.
The current amount of amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).
Amount of accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position.
The amount of cash, investment securities and interest receivable.
Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) unrealized gain less than 12 months.
Amount of accumulated unrealized gain on investment in debt security measured at fair value with change in other comprehensive income (available-for-sale), unrealized gain for less than 12 months.
Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next rolling three to twelve months.
Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next rolling three to twelve months.
Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) with single maturity date and allocated without single maturity date, maturing in next rolling three months.
Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next rolling three months.
Deferred finance charges.
Information pertaining to the business acquisition of EGEN, Inc.
The disclosure related to earn-out milestone liabilities.
Represents first 50% of a warrant issued.
First Tranche [Member]
The amount recognized in earnings related to the change in fair value during the period of milestone liability.
Glioblastoma Multiforme Brain Cancer [Member]
Represents a loan agreement with Hercules Technology Growth Capital, Inc. (“Hercules”).
Represents Hercules Technology Growth Capital, Inc..
Hercules Technology Growth Capital, Inc. [Member]
Represents Hercules Technology Growth Capital, Inc..
IPR&D Drug Technology Platforms [Member]
The entire disclosure for a contractual arrangement, in which the Company gave another party an exclusive license.
Loan Agreement [Member]
Represents the total number of Shares of common stock issuable upon exercise of warrants and equity awards.
Ovarian Cancer [Member]
Purchase Agreement [Member]
The disclosure of transactions regarding the changes in earn-out liabilities during the period.
Tabular disclosure of the cost, fair value and maturities of short-term investments.
Tabular disclosure of the risk-adjustment assessment of each milestone.
The tabular disclosure for share-based compensation, stock options and restricted stock awards, activity.
Represents second fifty percent of a warrant issued.
Second Tranche [Member]
2007 Stock Incentive Plan [Member]
2001 and 2004 Stock Incentive Plan [Member]
Percentage of fair market value of shares
Percentage of outstanding stock determining factor for incentive stock price.
Warrant date.
Equity Stock Awards [Member]
The percentage of risk-adjusted assessment of each milestone.
The amount of gain (loss) from the change in the fair value of earn-out milestone liability.
The amount of estimated time to achieve the milestone.
The amount of earn-out milestone liability as of the balance sheet.
Business combination contingent consideration liability discount rate.
Lawrenceville New Jersey [Member]
The number of months in which free rent is provided.
Represents the reduction of the contractual obligation that will occur nineteen months from initial term.
The remaining amount due under contractual obligations.
Represents the payment to be paid each month in the first year under an operating lease.
Represents the payment to be paid each month in the final year under an operating lease.
Represents the payment to be paid each month under an operating lease.
Huntsville Alabama [Member]
EGEN Asset Purchase Agreement [Member]
The amortization period for deferred revenue.
Hisun [Member]
Underwriting Agreement [Member]
Oppenheimer & Co. Inc. [Member]
Investor Warrants [Member]
Represents the October 2017 Underwritten Offering.
Represents the information pertaining to the direct offering agreement on July 6, 2017.
Represents the information pertaining to the Pre-Funded Series CCC Warrants.
Represents the information pertaining to the Series AAA Warrants.
Represents the information pertaining to the Series BBB Warrants.
Represents the information pertaining to Series DDD Warrants.
Represents the public offering on February 14, 2017.
Information relating to Series AA warrants.
Information relating to Pre-Funded Series BB Warrant.
Represents the information pertaining to the 2013 Warrants, 2014 Warrants, and June 2016 Warrants.
Represents the information pertaining to the 2015 Warrants.
Represents a securities purchase agreement with certain investors into which the entity entered in May 2015.
Represents Controlled Equity Offering Sales Agreement (the “ATM Agreement”) with Cantor Fitzgerald & Co., as sales agent.
The conversion of a reverse stock split where there is a reduction in the shares outstanding.
Shelf Registration statement.
The aggregate maximum number of common shares and nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
Offered price per share or per unit of warrants or rights.
The number of years after which warrants issued are set to expire.
The cash inflow from the additional capital contribution to the entity and from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).
The period in which the warrants or rights are exercisable.
The cash inflow from the additional capital contribution to the entity before the deduction of costs related to the issuance (for example, the placement agent fee and offering expenses).
Beneficial ownership percentage threshold for purchase of shares of company's common stock.
The number of warrants or rights exercised during period.
Period of time the warrants or rights are issued, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
Represents the maximum beneficial ownership of the Purchaser.
The number of new stock issued with the exercise of warrants during the period.
The amount of increase (decrease) in the fair value of warrants exercised.
Commission on Proceeds from ATM Shares, Percent
Aggregate offering price, remaining amount.
June 2016 Warrants [Member]
Aggregate offering price.
Dividends deemed that are related to warrant modifications..
Refund (deposit) on corporate office lease.
Fair value of warrants issued in connection with the notes payable.
Warrants [Text Block]
New Jersey [Member]
Horizon Technology Finance Corporation [Member]
Horizon Credit Agreement [Member]
Horizon Warrants [Member]
Horizon [Member]
2018 Stock Incentive Plan [Member]
Expected forfeiture rate.
Weighted average exercise price warrants outstanding.
Weighted Average Exercise Price Warrants issued.
Number of warrants issued aggregate intrinsic value of outstanding warrants.
Number of warrants issued weighted average remaining contractual terms.
Precentage of outstanding principle balance, description.
Tabular disclosure of warrant activity.
Net authorized amount percentage.
Assets, Current
Assets, Noncurrent
Assets
Liabilities, Current
Liabilities
Stockholders' Equity before Treasury Stock
Treasury Stock, Value
Stockholders' Equity Attributable to Parent
Liabilities and Equity
Operating Expenses
Operating Income (Loss)
Interest and Debt Expense
Nonoperating Income (Expense)
Weighted Average Number of Shares Outstanding, Basic and Diluted
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax
Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent
Comprehensive Income (Loss), Net of Tax, Attributable to Parent
Increase (Decrease) in Deposit Assets
Increase (Decrease) in Prepaid Expense and Other Assets
Net Cash Provided by (Used in) Operating Activities
Payments to Acquire Available-for-sale Securities
RefundDepositOnCorporateOfficeLease
Payments to Acquire Property, Plant, and Equipment
Net Cash Provided by (Used in) Investing Activities
Repayments of Notes Payable
Net Cash Provided by (Used in) Financing Activities
Cash and Cash Equivalents, Period Increase (Decrease)
Cost
WarrantsTextBlock
Cost [Default Label]
Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value
Less than 12 months, unrealized gains, fair value
Less than 12 months, unrealized gains
Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss
Unrealized gains (losses)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net
Long-term Debt, Gross
Debt Instrument, Unamortized Discount (Premium), Net
Long-term Debt
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value
clsn_EarnoutMilestoneLiability
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number
WeightedAverageExercisePriceVested
Deferred Revenue